Brodtkorb TH, Knight C, Kamgar F, Teitsson S, et al. Cost-effectiveness of nivolumab versus surveillance for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence: a US payer perspective. J Med Econ 2024;27:543-553.
PMID: 38470512